New Delhi: Ranbaxy Laboratories Ltd has launched its once-a-day nasal spray Osonose (Ciclesonide) aqueous in India. The nasal spray is prescribed for use in treatment of perennial and seasonal allergic rhinitis.

Sanjeev Dani, senior VP & regional director (Asia & CIS), Ranbaxy, said, “The launch of Osonose underpins our commitment to provide contemporary patient friendly solutions for the effective management of respiratory disorders like seasonal and perennial allergic rhinitis.”

“Today Ranbaxy offers an extensive range of innovative products in the asthma segment with novel delivery mechanisms such as dry powder inhalers (DPIs) and pMDIs, which are hydro fluoro alkane (HFA)  - environment friendly propellant - technology based inhalers, and nasal sprays to suit the convenience of patients,” Dani added.

A release of company stated that company has introduced the nasal spray in 50mcg strength. About 10 to 25 percent of global population is affected by allergic rhinitis, and is believed to a precursor of Asthma.